254 related articles for article (PubMed ID: 20516450)
1. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer.
Altorki N; Lane ME; Bauer T; Lee PC; Guarino MJ; Pass H; Felip E; Peylan-Ramu N; Gurpide A; Grannis FW; Mitchell JD; Tachdjian S; Swann RS; Huff A; Roychowdhury DF; Reeves A; Ottesen LH; Yankelevitz DF
J Clin Oncol; 2010 Jul; 28(19):3131-7. PubMed ID: 20516450
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of pazopanib in patients with advanced cancer.
Hurwitz HI; Dowlati A; Saini S; Savage S; Suttle AB; Gibson DM; Hodge JP; Merkle EM; Pandite L
Clin Cancer Res; 2009 Jun; 15(12):4220-7. PubMed ID: 19509175
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
[TBL] [Abstract][Full Text] [Related]
4. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.
Liao Z; Komaki R; Milas L; Yuan C; Kies M; Chang JY; Jeter M; Guerrero T; Blumenschien G; Smith CM; Fossella F; Brown B; Cox JD
Clin Cancer Res; 2005 May; 11(9):3342-8. PubMed ID: 15867233
[TBL] [Abstract][Full Text] [Related]
5. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer.
Friedlander M; Hancock KC; Rischin D; Messing MJ; Stringer CA; Matthys GM; Ma B; Hodge JP; Lager JJ
Gynecol Oncol; 2010 Oct; 119(1):32-7. PubMed ID: 20584542
[TBL] [Abstract][Full Text] [Related]
6. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M
J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of oral topotecan in advanced non-small cell lung cancer.
White SC; Cheeseman S; Thatcher N; Anderson H; Carrington B; Hearn S; Ross G; Ranson M
Clin Cancer Res; 2000 Mar; 6(3):868-73. PubMed ID: 10741709
[TBL] [Abstract][Full Text] [Related]
8. Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity.
Rosell R; González-Larriba JL; Alberola V; Molina F; Monzó M; Benito D; Pérez JM; de Anta JM
Semin Oncol; 1995 Dec; 22(6 Suppl 14):12-8. PubMed ID: 8553077
[TBL] [Abstract][Full Text] [Related]
9. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
Cohen RB; Langer CJ; Simon GR; Eisenberg PD; Hainsworth JD; Madajewicz S; Cosgriff TM; Pierce K; Xu H; Liau K; Healey D
Cancer Chemother Pharmacol; 2007 Jun; 60(1):81-9. PubMed ID: 17031646
[TBL] [Abstract][Full Text] [Related]
10. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.
Monk BJ; Mas Lopez L; Zarba JJ; Oaknin A; Tarpin C; Termrungruanglert W; Alber JA; Ding J; Stutts MW; Pandite LN
J Clin Oncol; 2010 Aug; 28(22):3562-9. PubMed ID: 20606083
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.
Greco FA; Bonomi P; Crawford J; Kelly K; Oh Y; Halpern W; Lo L; Gallant G; Klein J
Lung Cancer; 2008 Jul; 61(1):82-90. PubMed ID: 18255187
[TBL] [Abstract][Full Text] [Related]
12. [The study of peri-operative chemotherapy in stage I-IIIa NSCLC].
Liao ML; Zhou YZ; Ding JA; Ni GX; Zhao JM; Chen WH; Han BH; Shen J; Bai H; Chen ZW; Ji H; Wang HM; Zhou Z
Zhonghua Yi Xue Za Zhi; 2003 Jun; 83(11):962-6. PubMed ID: 12899797
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.
Rizvi NA; Riely GJ; Azzoli CG; Miller VA; Ng KK; Fiore J; Chia G; Brower M; Heelan R; Hawkins MJ; Kris MG
J Clin Oncol; 2008 Feb; 26(4):639-43. PubMed ID: 18235124
[TBL] [Abstract][Full Text] [Related]
14. An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone.
Yovino S; Kwok Y; Krasna M; Bangalore M; Suntharalingam M
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1438-43. PubMed ID: 16029805
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors.
Heath EI; Chiorean EG; Sweeney CJ; Hodge JP; Lager JJ; Forman K; Malburg L; Arumugham T; Dar MM; Suttle AB; Gainer SD; LoRusso P
Clin Pharmacol Ther; 2010 Dec; 88(6):818-23. PubMed ID: 20980999
[TBL] [Abstract][Full Text] [Related]
16. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
Sternberg CN; Hawkins RE; Wagstaff J; Salman P; Mardiak J; Barrios CH; Zarba JJ; Gladkov OA; Lee E; Szczylik C; McCann L; Rubin SD; Chen M; Davis ID
Eur J Cancer; 2013 Apr; 49(6):1287-96. PubMed ID: 23321547
[TBL] [Abstract][Full Text] [Related]
17. An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.
Sternberg CN; Davis ID; Deen KC; Sigal E; Hawkins RE
Oncology; 2014; 87(6):342-50. PubMed ID: 25227656
[TBL] [Abstract][Full Text] [Related]
18. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.
Necchi A; Mariani L; Zaffaroni N; Schwartz LH; Giannatempo P; Crippa F; Morosi C; Lanocita R; Sava T; Ortega C; Messina C; Sacco C; Pennati M; Daidone MG; Nicolai N; De Braud F; Gianni AM; Salvioni R
Lancet Oncol; 2012 Aug; 13(8):810-6. PubMed ID: 22819172
[TBL] [Abstract][Full Text] [Related]
19. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.
Nikolinakos PG; Altorki N; Yankelevitz D; Tran HT; Yan S; Rajagopalan D; Bordogna W; Ottesen LH; Heymach JV
Cancer Res; 2010 Mar; 70(6):2171-9. PubMed ID: 20215520
[TBL] [Abstract][Full Text] [Related]
20. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics.
Yau T; Chen PJ; Chan P; Curtis CM; Murphy PS; Suttle AB; Gauvin J; Hodge JP; Dar MM; Poon RT
Clin Cancer Res; 2011 Nov; 17(21):6914-23. PubMed ID: 21831954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]